Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

318.92 -4.06 (-1.26%)
Streaming Delayed Price Updated: 12:23 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces New Management Appointments
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.